

07 Apr 2024 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs first ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 5 April 2024, including: [\*Genmab A/S\*](#) buys into ADCs; [\*Roivant Sciences\*](#) set to take on [\*AbbVie Inc.\*](#) in uveitis; [\*Ipsen SA\*](#) signs first ADC pact; South Korea looks to build biotech momentum; and the end of the road for [\*Acorda Therapeutics, Inc.\*](#)

This and all our other podcasts are available on the *Citeline* channel on [\*Apple Podcasts\*](#), [\*Google Podcasts\*](#), [\*SoundCloud\*](#), [\*TuneIn\*](#) and [\*Spotify Podcasts\*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[\*Genmab Adds To Sector ADC Buying Spree With \\$1.8bn ProfoundBio Acquisition\*](#)" - *Scrip*, 3 Apr, 2024.)

(Also see "[\*Roivant May Take On AbbVie In Uveitis With Strong Phase II Efficacy\*](#)" - *Scrip*, 2 Apr, 2024.)

(Also see "[\*Ipsen Dives Back Into Dealmaking With First ADC Pact\*](#)" - *Scrip*, 2 Apr, 2024.)

(Also see "[\*Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative\*](#)" - Scrip, 31 Mar, 2024.)

(Also see "[\*All Over For Acorda After A Torrid Few Years\*](#)" - Scrip, 3 Apr, 2024.)

[Click here to explore this interactive content online](#) ✨